The trial included patients with earlier stage disease who are normally considered lower risk than the high-risk population.
Adding the CDK4/6 inhibitor ribociclib (Kisqali, Novartis) to hormonal therapy made cancer 25% less likely to return for those patients with hormone receptor (HR) positive, HER2-negative early-stage breast cancer (EBC), according to results to be presented today at the 2023 Annual Meeting of the American Society of Clinical Oncology.
Interim findings from the NATALEE trial (NCT03701334) could have widespread impact, as HR+/HER- breast cancer accounts for 70% of all new breast cancer cases, according to National Institutes of Health data. NATALEE enrolled patients with stage II and stage III HR+/HER2- early breast cancer (EBC), regardless of nodal involvement. The primary end point, invasive disease-free survival (iDFS), measures whether a patient’s cancer has returned.
“NATALEE is different from some other early breast cancer studies with CKD4/6 [inhibitors] in 3 important ways,” said lead investigator Dennis J. Slamon, MD, PhD, medical oncologist at UCLA Health. In a press briefing, Slamon listed the ways the trial broke new ground:
The trial randomized 5101 men and premenopausal and postmenopausal women with breast cancer who were at risk of recurrence. Patients received either adjuvant ribociclib with hormonal therapy (2549 patients) or hormonal therapy alone (2552 patients). After a median follow-up of 34 months, 20.2% of those in the ribociclib group completed 3 years of therapy and 56.8% completed 2 years of treatment.
The prespecified analysis evaluated data once there were 426 iDFS events. Data being presented at ASCO show 189 people in the ribociclib group (7.4% of patients) had a cancer recurrence, compared with 237 people in the hormonal therapy alone group (9.2% of patients).
Pairing ribociclib with hormonal therapy created significant improvement in survival. Results showed:
“Based on the numbers of patients that are challenged with this subtype of disease,” Slamon said, the findings “could result in a significant efficacy improvement.”
He noted that findings were consistent across subgroups, disease stage, menopausal status, and even nodal status. “So that means even patients with node negative disease—which are normally thought to be those with lower risk disease—they benefited as well,” he said.
Slamon noted that the reduced dose appeared to improve some safety signals in cardiotoxicity.
“While early, these results are very promising and suggest that there will be a role for adjuvant ribociclib for stage II and higher hormone receptor-positive (HR-positive), HER2- negative breast cancer,” said commentator Rita Nanda, MD, associate professor of medicine, University of Chicago.
The NATALEE study protocol calls for ongoing follow-up to evaluate long-term outcomes, including overall survival.
The January 2023 update to the National Comprehensive Cancer Network (NCCN) clinical guidelines for breast cancer recommends ribociclib as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- metastatic breast cancer when combined with an aromatase inhibitor.
In March, when Novartis officials announced topline results for NATALEE, they said it represented the broadest patient population of any CDK4/6 inhibitor trial to date. Citing data published in the New England Journal of Medicine, officials said 30% to 60% of the patient population represented in the NATALEE trial currently remains at risk of breast cancer recurrence with endocrine therapy only, and that EBC represents more than 90% of patients with breast cancer.
Reference
Slamon DJ, Stroyakovskjy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase 3 NATALEE trial. J Clin Oncol. 2023;41(suppl 17):abstr LBA500
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More